IDEAYA Biosciences, Inc.
corporate_fare Company Profile
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for IDYA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 13 rated 8 or above. Recent SEC coverage for IDYA spans 10-Q, 8-K, 424B5.
Recent high-impact activity:
- IDEAYA Q3: $1.15B Cash, Wider $125.7M Loss, Phase 3 OptimUM-010 Halted
- IDEAYA Halts Phase 3 Eye Cancer Trial, Frees $100-125M for ADC Push
- Three ESMO Datasets Back Darovasertib as Foundational Uveal Melanoma Therapy
- IDEAYA Expands Roche Tie-Up: Genentech to Test IDE892 With KRAS G12D Inhibitor in Pancreatic Cancer
- IDEAYA Q2 2026: $1.24B Cash Runway, Darovasertib NDA on Track, Pipeline Momentum Builds
Financial Snapshot
Short Interest & Short Volume
8.87 days to coverFINRA reported short interest of 8,236,480 shares in IDYA as of the October 30, 2026 settlement, a 9.3% decrease from the prior period — about 8.9 days to cover at its recent average daily volume. On November 19, 2026, 41.3% of IDYA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IDYA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.
Public Offering Priced · Significant Discounted Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →